B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Agenus (AGEN – Research Report) today and set a price target of $8.00. The company's shares closed last Friday at $1.49, close to its 52-week low of $1.40. According to TipRanks.com, Mamtani has 0 stars on 0-5 stars ranking scale with an average return of -30.7% and a 21.4% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Agenus with a $8.00 average price target.
https://www.tipranks.com/news/blurbs/b-riley-financial-thinks-agenus-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral